E M Olson1, M Abdel-Rasoul, J Maly, C S Wu, N U Lin, C L Shapiro. 1. Division of Medical Oncology, Department of Internal Medicine, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, USA. erin.olson@osumc.edu
Abstract
BACKGROUND: Central nervous system (CNS) disease as the site of first relapse after exposure to adjuvant trastuzumab has been reported. We carried out comprehensive meta-analysis to determine the risk of CNS metastases as the first site of recurrence in patients with HER2-positive breast cancer who received adjuvant trastuzumab. METHODS: Eligible studies include randomized trials of adjuvant trastuzumab administered for 1 year to patients with HER2-positive breast cancer who reported CNS metastases as first site of disease recurrence. Statistical analyses were conducted to calculate the incidence, relative risk (RR), and 95% confidence intervals (CIs) using fixed-effects inverse variance and random-effects models. RESULTS: A total of 9020 patients were included. The incidence of CNS metastases as first site of disease recurrence in HER2-positive patients receiving adjuvant trastuzumab was 2.56% (95% CI 2.07% to 3.01%) compared with 1.94% (95% CI 1.54% to 2.38%) in HER2-positive patients who did not receive adjuvant trastuzumab. The RR of the CNS as first site of relapse in trastuzumab-treated patients was 1.35 (95% CI 1.02-1.78, P = 0.038) compared with control arms without trastuzumab therapy. The ratio of CNS metastases to total number of recurrence events was 16.94% (95% CI 10.85% to 24.07%) and 8.33% (95% CI 6.49% to 10.86%) for the trastuzumab-treated and control groups, respectively. No statistically significant differences were found based on trastuzumab schedule or median follow-up time. No evidence of publication bias was observed. CONCLUSIONS: Adjuvant trastuzumab is associated with a significant increased risk of CNS metastases as the site of first recurrence in HER2-positive breast cancer patients.
BACKGROUND:Central nervous system (CNS) disease as the site of first relapse after exposure to adjuvant trastuzumab has been reported. We carried out comprehensive meta-analysis to determine the risk of CNS metastases as the first site of recurrence in patients with HER2-positive breast cancer who received adjuvant trastuzumab. METHODS: Eligible studies include randomized trials of adjuvant trastuzumab administered for 1 year to patients with HER2-positive breast cancer who reported CNS metastases as first site of disease recurrence. Statistical analyses were conducted to calculate the incidence, relative risk (RR), and 95% confidence intervals (CIs) using fixed-effects inverse variance and random-effects models. RESULTS: A total of 9020 patients were included. The incidence of CNS metastases as first site of disease recurrence in HER2-positive patients receiving adjuvant trastuzumab was 2.56% (95% CI 2.07% to 3.01%) compared with 1.94% (95% CI 1.54% to 2.38%) in HER2-positive patients who did not receive adjuvant trastuzumab. The RR of the CNS as first site of relapse in trastuzumab-treated patients was 1.35 (95% CI 1.02-1.78, P = 0.038) compared with control arms without trastuzumab therapy. The ratio of CNS metastases to total number of recurrence events was 16.94% (95% CI 10.85% to 24.07%) and 8.33% (95% CI 6.49% to 10.86%) for the trastuzumab-treated and control groups, respectively. No statistically significant differences were found based on trastuzumab schedule or median follow-up time. No evidence of publication bias was observed. CONCLUSIONS: Adjuvant trastuzumab is associated with a significant increased risk of CNS metastases as the site of first recurrence in HER2-positive breast cancerpatients.
Entities:
Keywords:
breast cancer; central nervous system; hER2; meta-analysis; metastases; trastuzumab
Authors: Aman U Buzdar; Vicente Valero; Nuhad K Ibrahim; Deborah Francis; Kristine R Broglio; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Sonja E Singletary; Kelly K Hunt; Aysegul A Sahin; Francisco Esteva; William F Symmans; Michael S Ewer; Thomas A Buchholz; Gabriel N Hortobagyi Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531
Authors: Aman U Buzdar; Nuhad K Ibrahim; Deborah Francis; Daniel J Booser; Eva S Thomas; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Banu K Arun; Sharon H Giordano; Massimo Cristofanilli; Debra K Frye; Terry L Smith; Kelly K Hunt; Sonja E Singletary; Aysegul A Sahin; Michael S Ewer; Thomas A Buchholz; Donald Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-02-28 Impact factor: 44.544
Authors: Erin M Olson; Julie S Najita; Jessica Sohl; Amal Arnaout; Harold J Burstein; Eric P Winer; Nancy U Lin Journal: Breast Date: 2013-01-23 Impact factor: 4.380
Authors: Gustavo A Viani; Sergio L Afonso; Eduardo J Stefano; Ligia I De Fendi; Francisco V Soares Journal: BMC Cancer Date: 2007-08-08 Impact factor: 4.430
Authors: David P Kodack; Vasileios Askoxylakis; Gino B Ferraro; Qing Sheng; Mark Badeaux; Shom Goel; Xiaolong Qi; Ram Shankaraiah; Z Alexander Cao; Rakesh R Ramjiawan; Divya Bezwada; Bhushankumar Patel; Yongchul Song; Carlotta Costa; Kamila Naxerova; Christina S F Wong; Jonas Kloepper; Rita Das; Angela Tam; Jantima Tanboon; Dan G Duda; C Ryan Miller; Marni B Siegel; Carey K Anders; Melinda Sanders; Monica V Estrada; Robert Schlegel; Carlos L Arteaga; Elena Brachtel; Alan Huang; Dai Fukumura; Jeffrey A Engelman; Rakesh K Jain Journal: Sci Transl Med Date: 2017-05-24 Impact factor: 17.956
Authors: Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman Journal: Pharm Res Date: 2016-08-15 Impact factor: 4.200
Authors: Nancy U Lin; Laleh Amiri-Kordestani; Diane Palmieri; David J Liewehr; Patricia S Steeg Journal: Clin Cancer Res Date: 2013-12-01 Impact factor: 12.531